- Home
- RGNX vs ALMS Comparison
RGNX vs ALMS Comparison
Compare RGNX & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- ALMS
- Stock Information
- Founded
- RGNX 2008
- ALMS 2021
- Country
- RGNX United States
- ALMS United States
- Employees
- RGNX N/A
- ALMS N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- ALMS
- Sector
- RGNX Health Care
- ALMS
- Exchange
- RGNX Nasdaq
- ALMS NYSE
- Market Cap
- RGNX 387.0M
- ALMS 402.6M
- IPO Year
- RGNX 2015
- ALMS 2024
- Fundamental
- Price
- RGNX $7.82
- ALMS $4.97
- Analyst Decision
- RGNX Strong Buy
- ALMS Strong Buy
- Analyst Count
- RGNX 8
- ALMS 7
- Target Price
- RGNX $31.75
- ALMS $28.00
- AVG Volume (30 Days)
- RGNX 1.0M
- ALMS 1.6M
- Earning Date
- RGNX 05-07-2025
- ALMS 05-15-2025
- Dividend Yield
- RGNX N/A
- ALMS N/A
- EPS Growth
- RGNX N/A
- ALMS N/A
- EPS
- RGNX N/A
- ALMS N/A
- Revenue
- RGNX $83,328,000.00
- ALMS N/A
- Revenue This Year
- RGNX $285.14
- ALMS N/A
- Revenue Next Year
- RGNX N/A
- ALMS N/A
- P/E Ratio
- RGNX N/A
- ALMS N/A
- Revenue Growth
- RGNX N/A
- ALMS N/A
- 52 Week Low
- RGNX $5.04
- ALMS $3.18
- 52 Week High
- RGNX $17.99
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- RGNX 59.58
- ALMS N/A
- Support Level
- RGNX $5.85
- ALMS N/A
- Resistance Level
- RGNX $6.83
- ALMS N/A
- Average True Range (ATR)
- RGNX 0.68
- ALMS 0.00
- MACD
- RGNX 0.11
- ALMS 0.00
- Stochastic Oscillator
- RGNX 99.64
- ALMS 0.00
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.